PE20030201A1 - Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion - Google Patents
Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacionInfo
- Publication number
- PE20030201A1 PE20030201A1 PE2002000522A PE2002000522A PE20030201A1 PE 20030201 A1 PE20030201 A1 PE 20030201A1 PE 2002000522 A PE2002000522 A PE 2002000522A PE 2002000522 A PE2002000522 A PE 2002000522A PE 20030201 A1 PE20030201 A1 PE 20030201A1
- Authority
- PE
- Peru
- Prior art keywords
- agent
- weight
- procedure
- preparation
- pharmaceutical formulation
- Prior art date
Links
- 239000000796 flavoring agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 235000019634 flavors Nutrition 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000003463 adsorbent Substances 0.000 abstract 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 abstract 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 229920006317 cationic polymer Polymers 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 abstract 1
- 229960003250 telithromycin Drugs 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
QUE COMPRENDE: a)DE 30 A 50% EN PESO DE UN POLIMERO CELULOSICO TAL COMO ETILCELULOSA, SOLUBLE EN DISOLVENTES ORGANICOS, PRACTICAMENTE INSOLUBLE EN AGUA, INDEPENDIENTEMENTE DE SU pH; b)DE 10% A 25%, EN PESO, DE UN POLIMERO CATIONICO FORMADO A PARTIR DE METACRILATO DE 2-DIMETILAMINOETILO Y METACRILATOS NEUTROS; Y c)HASTA 50%, EN PESO, DE TELITROMICINA COMO PRINCIPIO ACTIVO DISTRIBUIDO DE MANERA HOMOGENEA Y EN FORMA DE MATRIZ ATOMIZADA; d) UN AGENTE ALCALINO COMO MEGLUMINA; e)UN AGENTE ADSORBENTE COMO SILICATO DE MAGNESIO Y ALUMINIO; f)UN AGENTE PLASTIFICANTE HIDROFOBO EN LA MATRIZ; g)UN AGENTE ANTIOXIDANTE; Y, g) CONSERVANTES, AGENTES EDULCORANTES, AGENTES ESPESANTES Y AROMATIZANTES. SE REFIERE TAMBIEN AL PROCEDIMIENTO DE PREPARACION DE LA FORMULACION FARMACEUTICA DESCRITA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0108157A FR2826274B1 (fr) | 2001-06-21 | 2001-06-21 | Formulation pharmaceutique au gout masque et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030201A1 true PE20030201A1 (es) | 2003-03-12 |
Family
ID=8864587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000522A PE20030201A1 (es) | 2001-06-21 | 2002-06-18 | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US7138138B2 (es) |
| EP (1) | EP1401397B1 (es) |
| JP (1) | JP4880871B2 (es) |
| CN (1) | CN1239149C (es) |
| AP (1) | AP1595A (es) |
| AR (1) | AR036096A1 (es) |
| AT (1) | ATE290366T1 (es) |
| AU (1) | AU2002329311B2 (es) |
| BG (1) | BG66314B1 (es) |
| BR (1) | BRPI0208998A2 (es) |
| CA (1) | CA2452239C (es) |
| CO (1) | CO5540278A2 (es) |
| CZ (1) | CZ299947B6 (es) |
| DE (1) | DE60203178T2 (es) |
| EA (1) | EA006016B1 (es) |
| EC (1) | ECSP034915A (es) |
| ES (1) | ES2236574T3 (es) |
| FR (1) | FR2826274B1 (es) |
| GT (2) | GT200200115AA (es) |
| HR (1) | HRP20031067B1 (es) |
| HU (1) | HUP0400799A3 (es) |
| IL (2) | IL159404A0 (es) |
| JO (1) | JO2325B1 (es) |
| MA (1) | MA27042A1 (es) |
| MX (1) | MXPA03011756A (es) |
| MY (1) | MY134340A (es) |
| NO (1) | NO332258B1 (es) |
| NZ (1) | NZ530042A (es) |
| OA (1) | OA12635A (es) |
| PA (1) | PA8548301A1 (es) |
| PE (1) | PE20030201A1 (es) |
| PL (1) | PL202090B1 (es) |
| PT (1) | PT1401397E (es) |
| SK (1) | SK285865B6 (es) |
| SV (1) | SV2003001098A (es) |
| TN (1) | TNSN03141A1 (es) |
| TW (1) | TWI228049B (es) |
| UA (1) | UA77960C2 (es) |
| UY (1) | UY27341A1 (es) |
| WO (1) | WO2003000225A2 (es) |
| ZA (1) | ZA200309479B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384921B2 (en) * | 2004-02-20 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | Polymorphic forms of 6-11 bicyclic ketolide derivatives |
| GB2419094A (en) * | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
| FR2882522B1 (fr) | 2005-02-25 | 2007-04-13 | Aventis Pharma Sa | Composition pharmaceutique solide comprenant de la telithromycine |
| US7384922B2 (en) * | 2005-05-04 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | 6-11 bridged oxime erythromycin derivatives |
| US20060264386A1 (en) * | 2005-05-17 | 2006-11-23 | Rongqi Sun | Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof |
| JP2009525300A (ja) * | 2006-02-03 | 2009-07-09 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 水難溶性のポリマー及び活性薬剤の混合物を含む医薬組成物 |
| US20100226979A1 (en) * | 2006-03-21 | 2010-09-09 | Jubilant Organosys Limited | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate |
| US20080181932A1 (en) * | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
| KR100935893B1 (ko) * | 2007-09-11 | 2010-01-07 | 국방과학연구소 | 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법 |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| JP5597204B2 (ja) | 2008-12-16 | 2014-10-01 | カールスベア アー／エス | 気相グラフティングによってヒドロキシル化された表面のコーティング |
| SG11201405895UA (en) | 2012-03-27 | 2014-10-30 | Cempra Pharmaceuticals Inc | Parenteral formulations for administering macrolide antibiotics |
| DE102012014848A1 (de) * | 2012-07-27 | 2012-10-31 | Heilerde-Gesellschaft Luvos Just GmbH & Co. KG | Heilerde-Zubereitung |
| RU2017104163A (ru) * | 2014-08-05 | 2018-09-06 | Семпра Фармасьютикалз, Инк. | Порошкообразные составы пероральных суспензий антибактериальных агентов |
| US10982177B2 (en) | 2017-09-18 | 2021-04-20 | The Clorox Company | Cleaning wipes with particular lotion retention and efficacy characteristics |
| CN114209661B (zh) * | 2022-02-21 | 2022-04-29 | 北京罗诺强施医药技术研发中心有限公司 | 呈细粒形式的固体药物组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2930409A1 (de) * | 1979-07-26 | 1981-02-12 | Bayer Ag | Spruehtrocknung von mikrokapseldispersionen |
| JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
| ZA945944B (en) * | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| AU9182498A (en) * | 1997-10-03 | 1999-04-27 | Elan Corporation, Plc | Taste masked formulations |
| IN191239B (es) * | 1999-06-11 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| ATE408614T1 (de) * | 2000-08-22 | 2008-10-15 | Basilea Pharmaceutica Ag | Neue macrolide mit antibakterieller wirkung |
-
2001
- 2001-06-21 FR FR0108157A patent/FR2826274B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-08 TW TW091109613A patent/TWI228049B/zh not_active IP Right Cessation
- 2002-05-09 JO JO200241A patent/JO2325B1/en active
- 2002-06-11 GT GT200200115AK patent/GT200200115AA/es unknown
- 2002-06-11 GT GT200200115A patent/GT200200115A/es unknown
- 2002-06-17 MY MYPI20022250A patent/MY134340A/en unknown
- 2002-06-18 PE PE2002000522A patent/PE20030201A1/es not_active Application Discontinuation
- 2002-06-18 UY UY27341A patent/UY27341A1/es not_active Application Discontinuation
- 2002-06-19 PA PA20028548301A patent/PA8548301A1/es unknown
- 2002-06-19 AR ARP020102300A patent/AR036096A1/es not_active Application Discontinuation
- 2002-06-19 SV SV2002001098A patent/SV2003001098A/es not_active Application Discontinuation
- 2002-06-21 JP JP2003506872A patent/JP4880871B2/ja not_active Expired - Fee Related
- 2002-06-21 HU HU0400799A patent/HUP0400799A3/hu unknown
- 2002-06-21 DE DE60203178T patent/DE60203178T2/de not_active Expired - Lifetime
- 2002-06-21 EP EP02764922A patent/EP1401397B1/fr not_active Expired - Lifetime
- 2002-06-21 TN TNPCT/FR2002/002158A patent/TNSN03141A1/fr unknown
- 2002-06-21 IL IL15940402A patent/IL159404A0/xx active IP Right Grant
- 2002-06-21 CN CNB028121465A patent/CN1239149C/zh not_active Expired - Fee Related
- 2002-06-21 CA CA2452239A patent/CA2452239C/fr not_active Expired - Fee Related
- 2002-06-21 PL PL366803A patent/PL202090B1/pl unknown
- 2002-06-21 BR BRPI0208998A patent/BRPI0208998A2/pt not_active IP Right Cessation
- 2002-06-21 AT AT02764922T patent/ATE290366T1/de active
- 2002-06-21 PT PT02764922T patent/PT1401397E/pt unknown
- 2002-06-21 WO PCT/FR2002/002158 patent/WO2003000225A2/fr not_active Ceased
- 2002-06-21 OA OA1200300340A patent/OA12635A/fr unknown
- 2002-06-21 EA EA200400061A patent/EA006016B1/ru not_active IP Right Cessation
- 2002-06-21 UA UA2004010425A patent/UA77960C2/uk unknown
- 2002-06-21 SK SK1592-2003A patent/SK285865B6/sk not_active IP Right Cessation
- 2002-06-21 HR HR20031067A patent/HRP20031067B1/xx not_active IP Right Cessation
- 2002-06-21 ES ES02764922T patent/ES2236574T3/es not_active Expired - Lifetime
- 2002-06-21 CZ CZ20033441A patent/CZ299947B6/cs not_active IP Right Cessation
- 2002-06-21 AU AU2002329311A patent/AU2002329311B2/en not_active Ceased
- 2002-06-21 AP APAP/P/2003/002927A patent/AP1595A/en active
- 2002-06-21 NZ NZ530042A patent/NZ530042A/en not_active IP Right Cessation
- 2002-06-21 MX MXPA03011756A patent/MXPA03011756A/es active IP Right Grant
-
2003
- 2003-12-05 ZA ZA2003/09479A patent/ZA200309479B/en unknown
- 2003-12-12 US US10/735,538 patent/US7138138B2/en not_active Expired - Lifetime
- 2003-12-15 NO NO20035581A patent/NO332258B1/no not_active IP Right Cessation
- 2003-12-16 BG BG108458A patent/BG66314B1/bg unknown
- 2003-12-16 IL IL159404A patent/IL159404A/en not_active IP Right Cessation
- 2003-12-16 MA MA27445A patent/MA27042A1/fr unknown
- 2003-12-18 EC EC2003004915A patent/ECSP034915A/es unknown
- 2003-12-19 CO CO03111139A patent/CO5540278A2/es active IP Right Grant
-
2006
- 2006-09-20 US US11/533,573 patent/US20070014857A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030201A1 (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion | |
| PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| BRPI0108449B8 (pt) | formulações de pasta aperfeiçoada, suas aplicações farmacêuticas, método para matar insetos, bem como processo para preparar as referidas formulações | |
| ATE546135T1 (de) | Hyaluronsäure-nanopartikel | |
| WO2004026231A3 (en) | Formulation for lipophilic agents | |
| HN2000000267A (es) | Oxazolidinonas substituidas y su uso | |
| BRPI0409516A (pt) | composição, uso de uma composição e processo de melhora da penetração de um ativo farmacêutico | |
| CR7614A (es) | Preparaciones de insulina acida con estabilidad mejorada | |
| WO2007128923A3 (fr) | Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation | |
| HN2002000247A (es) | Derivados de sulfonamida | |
| WO2005009356A3 (en) | Method for the preparation of controlled release formulations | |
| WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
| WO2005000241A3 (en) | Compositons and methods for topical administration | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CU22836A3 (es) | Sistema de gel de nimesulida para uso tópico | |
| WO2007064968A3 (en) | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate | |
| CA2429205A1 (en) | Dermatological formulations | |
| BRPI0410958B8 (pt) | composição aquosa agroquímica | |
| DE602004014964D1 (de) | Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel | |
| BRPI0511387A (pt) | composição e seu uso | |
| BR0210063A (pt) | Composição estável e uso da mesma | |
| AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica | |
| WO2006100692A3 (en) | A novel inter and intra multilamellar vesicular composition. | |
| WO2001045727A3 (en) | Stabilized veterinary compositions comprising more than one antiviral agent | |
| WO2000067732A3 (de) | Pharmazeutische zusammensetzung enthaltend antimykotikum, polydocanol und salycylsaüre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |